{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:27:49Z","timestamp":1773278869444,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,2,17]],"date-time":"2006-02-17T00:00:00Z","timestamp":1140134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1007\/s00520-005-0918-0","type":"journal-article","created":{"date-parts":[[2006,2,16]],"date-time":"2006-02-16T01:40:10Z","timestamp":1140054010000},"page":"400-407","source":"Crossref","is-referenced-by-count":48,"title":["Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy"],"prefix":"10.1007","volume":"14","author":[{"given":"Carla","family":"Ripamonti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Fagnoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Campa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"De Conno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,2,17]]},"reference":[{"key":"918_CR1","volume-title":"Cancer pain relief","author":"World Health Organization","year":"1986","unstructured":"World Health Organization (1986) Cancer pain relief. World Health Organization, Geneva, Switzerland"},{"key":"918_CR2","volume-title":"Cancer pain relief, 2nd edn","author":"World Health Organization","year":"1996","unstructured":"World Health Organization (1996) Cancer pain relief, 2nd edn. World Health Organization, Geneva, Switzerland"},{"key":"918_CR3","unstructured":"World Health Organization (1999) Model list of essential drugs (EDL), 11th edn. Available at http:\/\/www.who.int\/medicines\/organization\/par\/edl\/infed 111 group.litml"},{"key":"918_CR4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bmj.312.7034.823","volume":"312","author":"GW Hanks","year":"1996","unstructured":"Hanks GW, De Conno F, Ripamonti C et al (Expert Working Group of the European Association for Palliative Care) (1996) Morphine in cancer pain: modes of administration. BMJ 312:823\u2013826","journal-title":"BMJ"},{"issue":"5","key":"918_CR5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1054\/bjoc.2001.1680","volume":"84","author":"GW Hanks","year":"2001","unstructured":"Hanks GW, De Conno F, Cherny N et al (Expert Working Group of the Research Network of the European Association for Palliative Care) (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84(5):587\u2013593","journal-title":"Br J Cancer"},{"key":"918_CR6","unstructured":"Jacox A, Carr DB, Payne R et al (Agency for Health Care Policy and Research (AHCPR) Pharmacological Management) (1994) Recommendations. In: Management of cancer pain. Clinical Practice Guideline No 9. U.S. Department of Health and Human Services, Public Health Service, AHCPR Publication No 94-0592, March, Rockville"},{"key":"918_CR7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1470-2045(00)00258-8","volume":"2","author":"GK Gourlay","year":"2001","unstructured":"Gourlay GK (2001) Treatment of cancer pain with transdermal fentanyl. Lancet Oncol 2:165\u2013172","journal-title":"Lancet Oncol"},{"key":"918_CR8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0140-6736(03)13819-6","volume":"362","author":"A Chinellato","year":"2003","unstructured":"Chinellato A, Terrazzani G, Walley T, Giusti P (2003) Opioids in Italy: is marketing more powerful than the law? Lancet 362:78","journal-title":"Lancet"},{"key":"918_CR9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1191\/0269216305pm1002oa","volume":"19","author":"F Conno De","year":"2005","unstructured":"De Conno F, Ripamonti C, Brunelli C (2005) Opioid purchases and expenditure in nine western European countries. \u201cAre we killing off morphine?\u201d Palliat Med 19:179\u2013184","journal-title":"Palliat Med"},{"issue":"2","key":"918_CR10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0885-3924(02)00445-1","volume":"24","author":"L Radbruch","year":"2002","unstructured":"Radbruch L, Nauck F, Sabatowski R (2002) Germany: Cancer pain and palliative care\u2014current situation. J Pain Symptom Manage 24(2):183\u2013187","journal-title":"J Pain Symptom Manage"},{"issue":"13","key":"918_CR11","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2165\/00002018-200326130-00004","volume":"26","author":"CA Kornik","year":"2003","unstructured":"Kornik CA, Santiago-Palma J, Moryl N, Payne R (2003) Benefit\u2013risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf 26(13):951\u2013973","journal-title":"Drug Saf"},{"issue":"23","key":"918_CR12","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.2165\/00003495-200464230-00002","volume":"64","author":"TL Skaer","year":"2004","unstructured":"Skaer TL (2004) Practice guidelines for transdermal opioids in malignant pain. Drugs 64(23):2629\u20132638","journal-title":"Drugs"},{"key":"918_CR13","volume-title":"Cancer pain guidelines","author":"Scottish Intercollegiate Guidelines Network (SIGN)","year":"2000","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN) (2000) Cancer pain guidelines. SIGN, Edinburgh"},{"key":"918_CR14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0304-3959(89)90130-9","volume":"37","author":"GK Gourlay","year":"1989","unstructured":"Gourlay GK, Kowalski SR, Plummer JL et al (1989) The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects. Pain 37:193\u2013202","journal-title":"Pain"},{"key":"918_CR15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0885-3924(95)00162-X","volume":"11","author":"W Korke","year":"1996","unstructured":"Korke W, de Stoutz N, Morant R (1996) Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manage 11:139\u2013146","journal-title":"J Pain Symptom Manage"},{"key":"918_CR16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000542-199301000-00007","volume":"78","author":"RK Portenoy","year":"1993","unstructured":"Portenoy RK, Southam MA, Gupta SK et al (1993) Transdermal fentanyl for cancer pain: repeated dose pharmacokinetics. Anesthesiology 78:36\u201343","journal-title":"Anesthesiology"},{"key":"918_CR17","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/00000542-198906000-00008","volume":"70","author":"JR Varvel","year":"1989","unstructured":"Varvel JR, Shaker SL, Hwang SS et al (1989) Absorption characteristics of transdermally administered fentanyl. Anesthesiology 70:928\u2013934","journal-title":"Anesthesiology"},{"key":"918_CR18","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/bja\/60.6.608","volume":"60","author":"FO Holley","year":"1988","unstructured":"Holley FO, Van Steennis C (1988) Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate IV and transdermal delivery: Br J Anaesth 60:608\u2013613","journal-title":"Br J Anaesth"},{"key":"918_CR19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0304-3959(90)91046-L","volume":"20","author":"GK Gourlay","year":"1990","unstructured":"Gourlay GK, Kowalski SR, Plummer JL et al (1990) The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems. Pain 20:21\u201328","journal-title":"Pain"},{"key":"918_CR20","first-page":"2225","volume":"21","author":"K Mystakidou","year":"2001","unstructured":"Mystakidou K, Befon S, Kouskouni E, Gerolymatos K, Georgaki S, Tsilika E, Vlahos L (2001) From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. Anticancer Res 21:2225\u20132230","journal-title":"Anticancer Res"},{"issue":"4","key":"918_CR21","first-page":"277","volume":"149","author":"M Burza","year":"1998","unstructured":"Burza M, Ginobbi P, Fusco G, Laurenzi L, Tirelli W, Arcuri E (1998) Transdermal route as an alternative to oral administration of opioids in cancer pain. Clin Ter 149(4):277\u2013280","journal-title":"Clin Ter"},{"issue":"6","key":"918_CR22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1185\/030079903125002045","volume":"19","author":"R Seventer Van","year":"2003","unstructured":"Van Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WWA (2003) Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 19(6):457\u2013469","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"918_CR23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1185\/030079903125003026","volume":"20","author":"MO Tawfik","year":"2004","unstructured":"Tawfik MO, Bryuzgin V and Kourteva G (FEN-INT-20 Study Group) (2004) Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Curr Med Res Opin 20(3):259\u2013267","journal-title":"Curr Med Res Opin"},{"key":"918_CR24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0885-3924(99)00152-9","volume":"19","author":"A Vielvoye-Kerkmeer","year":"2000","unstructured":"Vielvoye-Kerkmeer A, Mattern C, Uitendaal MP (2000) Transdermal fentanyl in opioid-na\u00efve cancer patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-na\u00efve patients and a group using codeine. J Pain Symptom Manage 19:185\u2013192","journal-title":"J Pain Symptom Manage"},{"key":"918_CR25","unstructured":"Janssen, LP (2005) Important drug warning. http:\/\/www.fda.gov\/medwatch\/SAFETY\/2005\/duragesic_ddl.pdf"},{"key":"918_CR26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0885-3924(97)00371-0","volume":"15","author":"A Megens","year":"1998","unstructured":"Megens A, Artois K, Vermeire J et al (1998) Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage 15:253\u2013257","journal-title":"J Pain Symptom Manage"},{"key":"918_CR27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0885-3924(97)00082-1","volume":"13","author":"S Ahmedzai","year":"1997","unstructured":"Ahmedzai S, Brooks D (1997) Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life\u2014the TTS-fentanyl Comparative Trial Group. J Pain Symptom Manage 13:254\u2013261","journal-title":"J Pain Symptom Manage"},{"key":"918_CR28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0304-3959(95)00180-8","volume":"64","author":"B Donner","year":"1996","unstructured":"Donner B, Zenz M, Tryba M et al (1996) Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 64:527\u2013534","journal-title":"Pain"},{"key":"918_CR29","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.1998.16.4.1588","volume":"16","author":"R Payne","year":"1998","unstructured":"Payne R, Mathias SD, Pasta DJ et al (1998) Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 16:1588\u20131593","journal-title":"J Clin Oncol"},{"key":"918_CR30","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1200\/JCO.2001.19.9.2542","volume":"19","author":"N Cherny","year":"2001","unstructured":"Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V (Expert Working Group the Research Network of EAPC) (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19:2542\u20132554","journal-title":"J Clin Oncol"},{"key":"918_CR31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1191\/026921600671594561","volume":"14","author":"L Radbruch","year":"2000","unstructured":"Radbruch L, Sabatowski R, Loick G, Kulbe C, Kasper M, Grond S, Lehmann KA (2000) Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 14:111\u2013119","journal-title":"Palliat Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-005-0918-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-005-0918-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-005-0918-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:01:35Z","timestamp":1559080895000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-005-0918-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,17]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["918"],"URL":"https:\/\/doi.org\/10.1007\/s00520-005-0918-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,17]]}}}